文献速递儿童消化与营养儿童感染

多菌株益生菌预防儿童抗生素相关腹泻的随机临床试验

Multispecies Probiotic for the Prevention of Antibiotic-Associated Diarrhea in Children: A Randomized Clinical Trial.
PubMed 文献 · JAMA Pediatr · 2022-01-01

按最严格定义,益生菌未降低抗生素相关腹泻风险(RR 0.81,95%CI 0.49-1.33),但降低了任何病因腹泻风险(RR 0.65,95%CI 0.44-0.94)。

要点

  • 多菌株益生菌未降低严格定义的抗生素相关腹泻风险。
  • 益生菌组任何病因腹泻风险低于安慰剂组。
  • 抗生素相关腹泻定义显著影响试验结果解读。

核心结论

  • 按最严格定义分析,多菌株益生菌未降低儿童抗生素相关腹泻风险。
  • 益生菌降低了抗生素治疗期间及结束后7天内任何病因腹泻的总体风险。
  • 抗生素相关腹泻的定义对临床试验结果及其解读有显著影响。

研究设计与样本

  • 随机、四盲、安慰剂对照试验,2018年2月至2021年5月在多中心混合场景(住院和门诊)开展。
  • 纳入年龄3月龄至18岁、开始广谱全身抗生素后24小时内招募并签署知情同意书的患者。
  • 共接触646名合格患者,350名参与试验,313名纳入意向性治疗分析。

主要发现

  • 益生菌组(n=158)与安慰剂组(n=155)相比,抗生素相关腹泻风险无差异(RR 0.81,95%CI 0.49-1.33)。
  • 益生菌组任何病因腹泻风险低于安慰剂组(RR 0.65,95%CI 0.44-0.94)。
  • 大多数次要结局包括不良事件在两组间无差异。

关键数值与推荐

  • 主要结局抗生素相关腹泻定义为24小时内3次及以上稀便或水样便,由艰难梭菌引起或经常见腹泻病原检测后原因不明。
  • 共350名儿童随机(192名男孩、158名女孩;平均[范围]年龄50[3-212]个月)。

临床怎么用

  • 不应期望多菌株益生菌能预防严格定义的儿童抗生素相关腹泻。
  • 可考虑其降低抗生素期间及结束后7天内任何病因腹泻风险的潜在获益。
  • 解读益生菌预防腹泻的试验时需注意抗生素相关腹泻定义的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The efficacy of multispecies probiotic formulations in the prevention of antibiotic-associated diarrhea (AAD) remains unclear. OBJECTIVE: To assess the effect of a multispecies probiotic on the risk of AAD in children. DESIGN, SETTING, AND PARTICIPANTS: This randomized, quadruple-blind, placebo-controlled trial was conducted from February 2018 to May 2021 in a multicenter, mixed setting (inpatients and outpatients). Patients were followed up throughout the intervention period. Eligibility criteria included age 3 months to 18 years, recruitment within 24 hours following initiation of broad-spectrum systemic antibiotics, and signed informed consent. In total, 646 eligible patients were approached and 350 patients took part in the trial. INTERVENTIONS: A multispecies probiotic consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, L acidophilus W55, Lacticaseibacillus paracasei W20, Lactiplantibacillus plantarum W62, Lacticaseibacillus rhamnosus W71, and Ligilactobacillus salivarius W24, for a total dose of 10 billion colony-forming units daily, for the duration of antibiotic treatment and for 7 days after. MAIN OUTCOMES AND MEASURES: The primary outcome was AAD, defined as 3 or more loose or watery stools per day in a 24-hour period, caused either by Clostridioides difficile or of otherwise unexplained etiology, after testing for common diarrheal pathogens. The secondary outcomes included diarrhea regardless of the etiology, diarrhea duration, and predefined diarrhea complications. RESULTS: A total of 350 children (192 boys and 158 girls; mean [range] age, 50 [3-212] months) were randomized and 313 were included in the intention-to-treat analysis. Compared with placebo (n = 155), the probiotic (n = 158) had no effect on risk of AAD (relative risk [RR], 0.81; 95% CI, 0.49-1.33). However, children in the probiotic group had a lower risk of diarrhea regardless of the etiology (RR, 0.65; 95% CI, 0.44-0.94). No differences were observed between the groups for most of the secondary outcomes, including adverse events. CONCLUSIONS AND RELEVANCE: A multispecies probiotic did not reduce the risk of AAD in children when analyzed according to the most stringent definition. However, it reduced the overall risk of diarrhea during and for 7 days after antibiotic treatment. Our study also shows that the AAD definition has a significant effect on clinical trial results and their interpretation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03334604.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Lukasik J, Dierikx T, Besseling-van der Vaart I, et al. Multispecies Probiotic for the Prevention of Antibiotic-Associated Diarrhea in Children: A Randomized Clinical Trial. JAMA Pediatr. 2022. PMID: 35727573. doi:10.1001/jamapediatrics.2022.1973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。